Fludarabine
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | FLUDARABINE PHOSPHATE | — | 2024-11-19 | fda.gov ↗ |
| Label expansion | US (FDA) | FLUDARA | — | 2003-08-01 | fda.gov ↗ |
| Approved | US (FDA) | FLUDARA | — | 1991-04-18 | fda.gov ↗ |
Trials 452 · started per year
Also used as a comparator or background therapy in 1,532 trials
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-12-04 | AbbVie | IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018 abbvie.com ↗ |
| 2004-04-29 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Fludarabine Phosphate Injection tevapharm.com ↗ |
Evidence & citations 30 cited values
Every value below carries the sentence it was read from. 1,991 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fludarabine | “RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4),...” NCT03412266 ↗1678“In the control arm, patients received other physician-directed regimen including fludarabine, cytarabine with/without granulocyte stimulating factor(FLA±G) regimen,cytarabine...” NCT02937662 ↗ “50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to...” NCT03295058 ↗ “* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine...” NCT06387069 ↗ “Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10\^9 to...” NCT01118091 ↗ “Lymphodepletion chemotherapy consisting of Fludarabine 30 mg/m2 IV once daily x 4 doses; and Cyclophosphamide 500mg/m2 IV once daily x 2 doses (starting with the first dose of...” NCT05010564 ↗ “SENTI-202 is administered in either a 3 dose regimen (Schedule 1: Days 0, 7, 14) or a 5 dose regimen (Schedule 2: Days 0, 3, 7, 10, 14) of a 28-day treatment cycle following a...” NCT06325748 ↗ “Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an...” NCT00145626 ↗ “Twenty-two children with a median age of 2.8 years, many with severe comorbidities and prior viral infections, were enrolled in a novel RIC protocol consisting of hydroxyurea,...” PMID 24296492 ↗ Dec 2013 “The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own...” NCT03526185 ↗ “Patients receive a preparative lymphodepleting chemotherapy of intravenous cyclophosphamide and fludarabine from day -5 until day -3 (or Bendamustine on day -3 and day -2),...” NCT07166549 ↗ “Patients will receive a non-myeloablative lymphodepleting regimen consisting of fludarabine and cyclophosphamide (FC) to induce lymphocyte depletion and create an optimal...” NCT06912529 ↗ “Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an...” NCT00145587 ↗ “Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted...” NCT00143559 ↗ “Resistant participants will receive a second induction with inotuzumab for B-cell precursor ALL or with FLAG-Ida (fludarabine, cytarabine, idarubicin and granulocyte colony...” NCT07443592 ↗ “RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4),...” NCT03412409 ↗ “Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced...” NCT03153462 ↗ “Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 +...” NCT04103879 ↗ “The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and...” NCT06468267 ↗ “Pre-treatment chemotherapy: Cyclophosphamide 500 mg/m² and Fludarabine 30 mg/m² will be administered intravenously on Days -5, -4, and -3 (with the day of Axicabtagene...” NCT06826118 ↗ “Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4,...” NCT01435447 ↗ “After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were...” NCT00147901 ↗ “Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant...” NCT00559221 ↗ “A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of...” NCT03790891 ↗ “Subjects will receive lymphodepletion pretreatment (Fludarabine/Cyclophosphamide), three SN301A intravenous infusions in a cycle (D0, D7, D14), with each subject receiving a...” NCT06652243 ↗ “Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the...” NCT06090864 ↗ “Subjects will receive cyclophosphamide 200 to 300 mg/m2 and fludarabine 20 to 30 mg/m2 once daily for 3 days either on Days -5, -4 and -3 or on Days -4, -3 and -2 prior to...” NCT07315503 ↗ “We hypothesized that lymphodepletion, achieved with cyclophosphamide (Cy) and fludarabine (Flu), would promote in vivo expansion of the infused lymphocytes enhancing their...” PMID 17579184 ↗ Jun 2007 “Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them...” NCT00863330 ↗ “In the second course patients are randomised between standard treatment with ADxE (cytarabine, DaunoXome, etoposide) or experimental therapy with FLADx (fludarabine,...” NCT01828489 ↗ “First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of...” NCT02354690 ↗ “Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell...” NCT01389427 ↗ “Patients received fludarabine and cyclophosphamide lymphodepleting preconditioning for three consecutive days-from day -5 (D-5) to day -3 (D-3)-prior to intravenous infusion of DQ1001” NCT07622862 ↗ “Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.” NCT04637269 ↗ “Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2.” NCT00772811 ↗ “High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).” NCT02920008 ↗ “A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).” NCT05472610 ↗ “A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).” NCT04250324 ↗ “Targeted total bone marrow and lymphoid irradiation (TMLI) conformal therapy administered in combination with a reduced-intensity regimen based on Fludarabine and Melphalan.” NCT06602323 ↗ “Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3 and Fludarabine 25mg/m2 IV on days -5 to -3.” NCT06728189 ↗ “Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).” NCT05141474 ↗ “Participants on fludarabine, cytarabine and granulocyte colony-stimulating factor (G-CSF) (FLAG) will receive 30 mg/m\^2 of fludarabine daily by IV for 5 days (day 2 to 6)” NCT05876832 ↗ “Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide” NCT02098512 ↗ “Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1.” NCT01049854 ↗ “Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation” NCT05870995 ↗ “According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.” NCT03638206 ↗ “Patients will receive Fludarabine (30mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3, followed by Anti-CD19 CAR NK cells infusion.” NCT06318533 ↗ “Drug: Cyclophosphamide and fludarabine Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to BAFF-R CART cells infusion on Day 0.” NCT07022197 ↗ “RNK001 infusion was supported by IP IL-2 in six patients, and was preceded in one patient by lymphodepleting chemotherapy with cyclophosphamide/fludarabine.” PMID 41289795 ↗ Nov 2025 “Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day” NCT06903117 ↗ “Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation.” NCT01208896 ↗ “Before initiating ThisCART19A infusion, subjects will be administered lymphodepletion chemotherapy composed of fludarabine、cyclophosphamide and VP-16.” NCT05679687 ↗ “All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.” NCT03142646 ↗ “Approximately 3-5 days prior to CD5 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion.” NCT07022964 ↗ “Standard treatment will include: * CAR T-cell therapy (either axicabtagene-ciloleucel or lisocabtagene maraleucel) * Cyclophosphamide * Fludarabine” NCT05934448 ↗ “Prior to infusion of the LCAR-M61SQ cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.” NCT06888752 ↗ “Prior to infusion of the LCAR- F33S cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.” NCT07100067 ↗ “Fludarabine injection (30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before RN1201 infusion.” NCT07105735 ↗ “Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide” NCT02766868 ↗ “Fludarabine (30 mg/m2 per day, from D-6 to D-3) and cyclophosphamide (2400 mg/ m2 x 2 days, on days -6 and -5) are administered as an IV infusion.” NCT06889766 ↗ “Intravenous infusions of cyclophosphamide and fludarabine administered for 3 consecutive days 3-5 days prior to receive lisocabtagene maraleucel.” NCT07711483 ↗ “cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy” NCT03913026 ↗ “Lymphodepletion chemotherapy with fludarabine (25 mg/m²/day) and cyclophosphamide (250 mg/m²/day) should be administered for 2-3 consecutive days” NCT07306156 ↗ “Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD2219-CAR-T cells.” NCT06834529 ↗ “Treatment consists of a conditioning regimen (cyclophosphamide and fludarabine), a single infusion of E7 TCR-T cells, and adjuvant aldesleukin.” NCT05686226 ↗ “A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells” NCT04191941 ↗ “Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan.” NCT00145613 ↗ “Prior to infusion of the LCAR-G08, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.” NCT06197178 ↗ “Patients will receive 30 mg/m2 per day intravenously of fludarabine for 5 days and 2000 mg/m2 per day intravenously of cytarabine for 5 days.” NCT03446638 ↗ “fludarabine and cyclophosphamide Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days” NCT03711864 ↗ “Resistant patients will receive a second induction with fludarabine, Ara-C, G-Colony-Stimulating Factor (G-CSF) and idarubicin (FLAG-IDA).” NCT04179929 ↗ “Fludarabine: 30 mg/m² per day, once daily for 3 consecutive days; Cyclophosphamide: 300 mg/m² per day, once daily for 3 consecutive days;” NCT07337785 ↗ “Venetoclax (Venclyxto®): 400 mg abs./d day -8 to -2, Fludarabine 30 mg/m2 BSA day -6 to day -2, Treosulfan 10 g/m2 BSA day -4 to day -2” NCT07214064 ↗ “Flu-Bu-ATG (Study A) associated Fludarabine (30mg/m²/5 days), Oral Busulfan (8 mg/kg over 2 days) and Thymoglobuline (2.5 mg/m²/1day).” NCT00894049 ↗ “conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation” NCT07284641 ↗ “CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.” NCT06549296 ↗ “The chemotherapy conditioning regimen is cyclophosphamide 500 mg/m\^2 daily for 3 days and fludarabine 30 mg/m\^2 daily for 3 days.” NCT05797233 ↗ “Lymphodepletion Conditioning: Chemotherapy (Cyclophosphamide + Fludarabine) before cell infusion to clear lymphocytes in the body.” NCT07366658 ↗ “Lymphodepleting chemotherapy ( fludarabine and cyclophosphamide) administered pre-infusion to facilitate CAR-NK cell engraftment.” NCT07589517 ↗ “CD30.CAR-T cells will be infused once following the completion of lymphodepleting chemotherapy with Bendamustine and Fludarabine.” NCT04526834 ↗ “The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7.” NCT01496547 ↗ “The transplant conditioning regimen will include fludarabine, melphalan, and alemtuzumab starting at Day -14 (Flu/Mel/Alem).” NCT01998633 ↗ “Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.” NCT00117598 ↗ “FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days” NCT05780879 ↗ “Prior to CAR-T cell infusion, subjects will receive lymphodepleting chemotherapy based on fludarabine and cyclophosphamide.” NCT07240857 ↗ “Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.” NCT06532630 ↗ “Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo” NCT01005745 ↗ “Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days” NCT06642025 ↗ “Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna.” NCT01328496 ↗ “reduced intensity conditioning regimen consisting of Fludarabine (150mg/m2) + Busulfan (6.4mg/kg) + Melphalan (70mg/m2)” NCT04904237 ↗ “Participants receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) followed by CAR-NK administration.” NCT07480954 ↗ “CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion” NCT06128044 ↗ “Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.” NCT04097301 ↗ “Conditioning chemotherapy: Cyclophosphamide 250 mg/m\^2 and fludarabine 30 mg/m\^2 IV infusion on days -5, -4, and -3” NCT04662099 ↗ “lymphodepleting therapy with fludarabine (adjusted based on renal impairment) and cyclophosphamide daily for 3 days.” NCT06655896 ↗ “Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3.” NCT06464679 ↗ “FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen” NCT02013167 ↗ “Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3.” NCT06469190 ↗ “Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3.” NCT05673447 ↗ “Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3.” NCT06792799 ↗ “recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day)” NCT04639739 ↗ “non-myeloablative lymphodepletion chemotherapy with cyclophosphamide and fludarabine administered on Days -4 to -2” NCT07593820 ↗ “Fludarabine 40 mg/m\^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m\^2).” NCT00392782 ↗ “Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide.” NCT04237428 ↗ “Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT.” NCT00096460 ↗ “Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.” NCT06316076 ↗ “Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection” NCT06767046 ↗ “lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours.” NCT05583149 ↗ “Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion.” NCT01659151 ↗ “Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3)” NCT02644655 ↗ “Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)” NCT06243159 ↗ “Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (25 mg/m2/day for 3 days)” NCT05727683 ↗ “Fludarabine (Fludara®, Schering AG, Berlin, Germany) 30 ㎎/㎡ i.v. over 30 minutes in D5W 100 ㎖ on days -6 to -2” NCT00774280 ↗ “Example regimen: fludarabine (Days -5 to -3) and cyclophosphamide (Days -5 to -4) prior to CAR-NK infusion.” NCT07480928 ↗ “lumiliximab added to fludarabine, cyclophosphamide, and rituximab (FCR) in previously treated CLL patients.” PMID 19843887 ↗ Oct 2009 “chemotherapy - fludarabine (Days -5 to -3) and cyclophosphamide (Days -5 to -4), prior to CAR-NK infusion.” NCT07510802 ↗ “Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days” NCT06515314 ↗ “Fludarabine:30 mg/m\^2 per day intravenous (IV) infusion over 30 minutes, daily on days -6, -5, -4, and -3” NCT02356159 ↗ “Drug: Fludarabine Two days before cell infusion, all patients will be treated with fludarabine for 3 days” NCT04537442 ↗ “concomitantly administered nonmyeloablative fludarabine, cyclophosphamide and total body irradiation (TBI)” NCT00004143 ↗ “Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3” NCT03196414 ↗ “with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days” NCT00910650 ↗ “Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3.” NCT06337474 ↗ “Drug: Fludarabine Recommendation: 25-30 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline.” NCT06209671 ↗ “Routine transplant chemotherapy agent fludarabine will be given on days -6 to -2 as daily IV infusions.” NCT06315309 ↗ “CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion” NCT06752876 ↗ “Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days” NCT03330834 ↗ “cyclophosphamide (Cy, 1000 mg/m2/day, day -6 to -5), and fludarabine (Flu, 25 mg/m2/day, day -6 to -2)” NCT04221971 ↗ “Routine transplant chemotherapy agent fludarabine will be given on days -7 to -3 as daily IV infusions” NCT06265584 ↗ “Fludarabine: 30mg/m² , dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 30minutes” NCT05438667 ↗ “Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses” NCT03874897 ↗ “Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine” NCT00875667 ↗ “Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses” NCT06170294 ↗ “Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.” NCT06006390 ↗ “Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.” NCT07247396 ↗ “Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses” NCT06348797 ↗ “Drug: Fludarabine Two days before cell infusion, patient will be treated with fludarabine for 3 days” NCT04766840 ↗ “Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.” NCT03191773 ↗ “The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.” NCT05667402 ↗ “Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline.” NCT06718738 ↗ “Drug: Fludarabine Recommendation: 25-30 mg/kg (D-5\~D-3), determined by tumor burden at baseline.” NCT05410041 ↗ “Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline.” NCT07406984 ↗ “Drug: Fludarabine Recommendation: 25-30 mg/m2 (D-5\~D-3), determined by tumor burden at baseline.” NCT05563545 ↗ “Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine.” NCT05639972 ↗ “Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan” NCT03882203 ↗ “IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days” NCT05292898 ↗ “Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes.” NCT03076437 ↗ “TC-G203 CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.” NCT07242417 ↗ “Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.” NCT00582816 ↗ “Fludarabine 30 mg/m2 IVPB daily from Day -6 (6 days before stem cell infusion) through Day -2” NCT04187105 ↗ “A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered” NCT07275736 ↗ “standardised conditioning regimen involving Fludarabine, Cyclophosphamide, Thiotepa, and TBI” NCT07372885 ↗ “A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered” NCT03720496 ↗ “Fludarabine + Cyclophosphamide administered on Days -5, -4, and -3 prior to CAR-NK infusion” NCT07641023 ↗ “Fludarabine + Cyclophosphamide administered on Days -5, -4, and -3 prior to CAR-NK infusion” NCT07467863 ↗ “fludarabine (Days -5 to -3) and cyclophosphamide (Days -5 to -4) prior to CAR-NK infusion.” NCT07627711 ↗ “Drug: Fludarabine Part of the non-myeloablative lymphocyte-depleting preparative regimen.” NCT05868915 ↗ “cyclophosphamide 1200 mg/m(2)/day IV for 4 days and fludarabine 30 mg/m(2)/day for 4 days” NCT00973804 ↗ “TC-D101 CAR-T treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.” NCT07246304 ↗ “Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa, clofarabine” NCT04761770 ↗ “Patients will receive Fludarabine and Cyclophosphamide for lymphodepletion conditioning.” NCT06421701 ↗ “Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide” NCT05877599 ↗ “Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy.” NCT07145450 ↗ “cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3” NCT04508842 ↗ “Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.” NCT05748197 ↗ “Cyclophosphamide 250 mg/m2 and fludarabine 30 mg/m2 IV infusion on day -5, -4, and -3.” NCT07168291 ↗ “lymphodepleting chemotherapy consisting of cyclophosphamide combined with fludarabine” NCT07535138 ↗ “after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide” NCT01947322 ↗ “WITH Fludarabine (IV) + Cyclophosphamide (IV), administered prior to CAR-NK infusion.” NCT07410494 ↗ “Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.” NCT00840385 ↗ “Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle” NCT00868413 ↗ “Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;” NCT04572308 ↗ “Drug: Cyclophosphamide (500 mg/m²) + Fludarabine (30 mg/m²), IV on Days -5, -4, -3.” NCT06902012 ↗ “associating Fludarabine, Thymoglobuline, and intravenous Busulfan with adapted dose” NCT02483325 ↗ “A combination of fludarabine and cyclophosphamide will be used for lymphodepletion.” NCT05768529 ↗ “Drug: Fludarabine Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3.” NCT05948033 ↗ “Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2” NCT04897139 ↗ “recommended Fludarabine and cyclophosphamide (unless contra-indicated for subject)” NCT03610724 ↗ “Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;” NCT04796441 ↗ “the patient will be pretreated with fludarabine and cyclophosphamide (FC) regimen” NCT06464185 ↗ “conditioning premedication regimen consisting of cyclophosphamide and fludarabine” NCT06472479 ↗ “RIC with alemtuzumab, fludarabine, and melphalan between March 2003 and May 2014” PMID 26348869 ↗ Oct 2015 “Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine)” NCT03570892 ↗ “Drug: Fludarabine + Cyclophosphamide+Oxaliplatin Fludarabine: 25mg/m²/day×3days” NCT05933668 ↗ “Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.” NCT03509961 ↗ “Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan” NCT05436561 ↗ “Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.” NCT06517641 ↗ “All patients will be treated with fludarabine and cyclophosphamide for 3 days” NCT04336501 ↗ “During Cycles 1 and 2, participants will receive fludarabine and cytarabine.” NCT05326516 ↗ “Patients will receive Fludarabine and Cyclophosphamide on day -5, -4, and -3” NCT07298590 ↗ “Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion” NCT03980288 ↗ “Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.” NCT05886491 ↗ “or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG)” NCT04716114 ↗ “FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2)” NCT03881761 ↗ “FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2)” NCT03881774 ↗ “The patients then receive fludarabine and cyclophosphamide on days-5 to-3.” NCT03767725 ↗ “fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)” NCT03836261 ↗ “* Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2” NCT00849147 ↗ “Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week” NCT05807659 ↗ “Busulfan, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF” NCT02053545 ↗ “Fludarabine: 40 mg/m\^2 intravenously (IV) on Days -6, -5, -4, -3, and -2” NCT00864227 ↗ “Patients will receive Fludarabine and Cyclophosphamide for conditioning.” NCT06614270 ↗ “Fludarabine 150mg/m2 + Busulfan 3.2mg/kg 2 days + melphalan 50-70mg/m2” NCT04269811 ↗ “Fludarabine (30 mg/m2/day) given intravenously (IV) on day -5 to -3.” NCT06027957 ↗ “FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5” NCT00909168 ↗ “Cyclophosphamide at 300 mg/m²/day plus Fludarabine at 30 mg/m²/day.” NCT07617285 ↗ “Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily.” NCT00520130 ↗ “FC regimen (fludarabine and cyclophosphamide) for lymphodepletion” NCT07003568 ↗ “fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose” NCT04815356 ↗ “Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses)” NCT05888493 ↗ “lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2)” NCT04499573 ↗ “4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes” NCT00580034 ↗ “4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes” NCT00578942 ↗ “Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2” NCT02991898 ↗ “fludarabine (intravenous infusion 30 mg/m2 per day on days 2-6)” PMID 31175001 ↗ Jun 2019 “fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day” NCT06768151 ↗ “F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks” NCT00391066 ↗ “F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks” NCT00801060 ↗ “Myeloablative regimen of busulfan, fludarabine, and thiotepa.” NCT06900192 ↗ “patients will be treated with cyclophosphamide or fludarabine” NCT03941626 ↗ “* fludarabine (F): 40 mg/m² orally, D2 to D4 - cycles 1 to 6.” NCT04010968 ↗ “Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;” NCT04447573 ↗ “Drug: Fludarabine Fludarabine is used for lymphodepletion.” NCT04844086 ↗ “ATG will be infused after fludarabine \& busulfan infusion.” NCT03456817 ↗ “Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2” NCT00997529 ↗ “fludarabine will be given for the next 3 days with 35mg/m2” NCT04627740 ↗ “Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -8 to -4” NCT01751997 ↗ “Fludarabine and cyclophosphamide as per standard of care.” NCT05020015 ↗ “Fludarabine 30mg/m2 daily on i.v. on days 2 - 6 inclusive” NCT02272478 ↗ “Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3)” NCT06412458 ↗ “Intravenous infusion of cyclophosphamide and fludarabine” NCT07388277 ↗ “fludarabine - cytarabine - idarubicin - G-CSF (FLAG-IDA)” NCT06713837 ↗ “fludarabine 30 mg/m\^2 daily by IV for 5 days (days 2-6)” NCT05586074 ↗ “Intravenous Infusion of Cyclophosphamide and Fludarabine” NCT07406724 ↗ “Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles” NCT00824265 ↗ “daily fludarabine at 40 mg/m2/d infused over 30 minutes” NCT00597714 ↗ “Drug: Fludarabine 30 mg/m2 i.v. for 3 consecutive days” NCT05211557 ↗ “lymphodepletion Drug: Fludarabine and Cyclophosphamide” NCT07108140 ↗ “Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2” NCT01860170 ↗ “preconditioning with fludarabine and cyclophosphamide” NCT06359041 ↗ “FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy” NCT05645601 ↗ “Patients will receive Fludarabine (25 mg/m2 per day)” NCT06010472 ↗ “30 mg/m2/day fludarabine for 5 days (day-6 to day-2)” NCT02876679 ↗ “Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)” NCT03035422 ↗ “Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2” NCT01597778 ↗ “Fludarabine: 30 mg/m\^2/day IV on Days -8 through -4” NCT00745420 ↗ “Cyclophosphamide, Fludarabine, Interleukin-2, Mesna” NCT00640796 ↗ “fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13” NCT01461837 ↗ “Drug: Fludarabine; chemotherapy for lymphodepletion” NCT05001451 ↗ “Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2” NCT00763490 ↗ “Fludara (fludarabine) - drug class: antimetabolite” NCT02626715 ↗ “Fludarabine 25 to 30 mg/m2, once daily for 3 days” NCT05930314 ↗ “Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3” NCT06185751 ↗ “subjects receive fludarabine at dose 30mg/m2/day” NCT04260932 ↗ “subjects receive fludarabine at dose 30mg/m2/day” NCT04260945 ↗ “Fludarabine 40 mg/m2 IV once daily days -7 to -4” NCT02084563 ↗ “Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)” NCT03079089 ↗ “subjects receive fludarabine at dose 30mg/m2/day” NCT03952923 ↗ “fludarabine IV over 30 minutes on days -8 to -4” NCT00054236 ↗ “intravenous fludarabine (30 mg/m2/d for 3 days)” NCT00603460 ↗ “Fludarabine (30mg/m2/day i.v: day -6 to day -2)” NCT06646497 ↗ “Day -6 Fludarabine at 25mg/m2 daily for 5 days” NCT02409576 ↗ “Cyclophosphamide + Fludarabine lymphodepletion” NCT07617753 ↗ “Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2” NCT05298358 ↗ “fludarabine (40mg/m2/d) from day -6 to day -3” NCT01220544 ↗ “FC regimen (fludarabine and cyclophosphamide)” NCT07003555 ↗ “Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2)” NCT05884333 ↗ “Fludarabine IV over 5-10 minutes on days 1-5.” NCT00053287 ↗ “fludarabine, thiotepa ,cyclophosphamide (FTC)” NCT04121507 ↗ “Drug: Fludarabine， Administered intravenously” NCT05613348 ↗ “Fludarabine and cyclophosphamide IV infusion.” NCT06377228 ↗ “The lymphodepleting regimen was: Fludarabine” NCT02445248 ↗ “Fludarabine Chemotherapy for lymphodepletion” NCT05722418 ↗ “Fludarabine 25 mg/m\^2 x 5 days start day -6” NCT01385423 ↗ “Fludarabine i.v.: 30 mg/m²/d (day -6 to -2)” NCT03963024 ↗ “fludarabine 30mg/ m2 for 3 consecutive days” NCT05315778 ↗ “Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3)” NCT06468683 ↗ “Drug: Fludarabine Lympho-conditioning Agent” NCT06027853 ↗ “Fludarabine 25 mg/day on day -5, -4 and -3” NCT04014894 ↗ “FC regimen: Fludarabine + Cyclophosphamide” NCT07097207 ↗ “FC regimen: Fludarabine + Cyclophosphamide” NCT07508605 ↗ “Fludarabine, Cytarabine, Idarubicin, G-CSF” NCT03257241 ↗ “Fludarabine 25 mg/m2 x 5 days start Day -6” NCT03081780 ↗ “FC regimen: Fludarabine + Cyclophosphamide” NCT07584889 ↗ “Fludarabine 25 mg/m2 x 5 days start day -6” NCT02395822 ↗ “Fludarabine 25 mg/m2 x 5 days start day -6” NCT03050216 ↗ “FC regimen: Fludarabine + Cyclophosphamide” NCT07399769 ↗ “fludarabine 30 mg/m²/day on days -6 to -2” NCT07562568 ↗ “* Fludarabine 30 mg/m\^2 on Days -5 to -3” NCT00912223 ↗ “fludarabine (30 mg/m2/day, days -6 to -2)” NCT07677306 ↗ “Conditioning regimen: fludarabine 30mg/m2” NCT06378060 ↗ “fludarabine (25 mg/m2 days -7, -6, \& -5)” NCT00676806 ↗ “Drug: Fludarabine Drug: Cyclophosphamide” NCT04230473 ↗ “Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3)” NCT06206902 ↗ “fludarabine (25mg/m2/d) on days -5 to -3” NCT05744037 ↗ “(e.g., fludarabine and cyclophosphamide)” NCT07480213 ↗ “Drug: Fludarabine and Cyclophosphamide.” NCT07487597 ↗ “fludarabine 30 mg/m²/d on days -6 to -2” NCT07588594 ↗ “Floxuridine, Fludarabine, Fluorouracil” NCT02788201 ↗ “Drug 1: Fludarabine + Cyclophosphamide” NCT06358053 ↗ “Drug: Fludarabine and Cyclophosphamide” NCT07123493 ↗ “fludarabine (25 mg/mE2/day IV x5days)” NCT00604136 ↗ “Drug: Fludarabine + Cyclophosphamide” NCT07139067 ↗ “Fludarabine 33 mg/m\^2 IV for 4 days” NCT00385788 ↗ “fludarabine 30 mg/m2/24h day-6 to -2” NCT01582048 ↗ “fludarabine phosphate (fludarabine)” NCT00801489 ↗ “Drug: Cyclophosphamide,Fludarabine;” NCT05206071 ↗ “Drug: Cyclophosphamide,Fludarabine” NCT04546906 ↗ “Drug: Cyclophosphamide,Fludarabine” NCT04546893 ↗ “Drug: Cyclophosphamide,Fludarabine” NCT04938115 ↗ “Fludarabine-Mitoxantrone-Rituximab” NCT00859001 ↗ “Drug: Cyclophosphamide,Fludarabine” NCT05618041 ↗ “Drug: Cyclophosphamide,Fludarabine” NCT04792593 ↗ “Fludarabine 25-30mg/m2 for 3 days” NCT03664661 ↗ “Fludarabine 25mg/ m2/day x 2 days” NCT05831033 ↗ “Drug: Fludarabine 25mg/m\^2 d1-3” NCT03170141 ↗ “fludarabine and cyclophosphamide” NCT06947460 ↗ “fludarabine 40 mg/m\^2 x 4 doses” NCT01370213 ↗ “Everolimus Fludarabine Gefitinib” NCT02551718 ↗ “fludarabine 25 mg/m2 IV x 5 days” NCT00587054 ↗ “Cyclophosphamide and Fludarabine” NCT06630611 ↗ “fludarabine and cyclophosphamide” NCT04727151 ↗ “Day -8: Fludarabine 30mg/m2 IV” NCT00920972 ↗ “Cylcophosamide and Fludarabine” NCT06748872 ↗ “fludarabine + cyclophosphamide” NCT07510828 ↗ “Fludarabine : 40 mg/m² per os” NCT02666898 ↗ “Fludarabine(30mg/m2,days 1-5)” NCT06084819 ↗ “F（Fludarabine）：25mg/m2·d，d1-3” NCT03980002 ↗ “Fludarabine 30 mg / m\^2 i.v.” NCT04206943 ↗ “Patients receive fludarabine” NCT03890198 ↗ “fludarabine (30mg/m2/day IV)” NCT03128996 ↗ “fludarabine 30 mg/m2/day x 3” NCT03070327 ↗ “fludarabine (30mg/m²/d ×3d)” NCT07441291 ↗ “fludarabine 30mg / m2 / d-5” NCT06769568 ↗ “fludarabine 25mg/m2/d×3day” NCT06945523 ↗ “fludarabine 25mg/m2/d×3day” NCT06992583 ↗ “Fludarabine days -8 to -4” NCT02165007 ↗ “Fludarabine 25 mg/m² Q3W” NCT04980859 ↗ “Busulfan and fludarabine” NCT06859424 ↗ “Drug: Fludarabine (FLU)” NCT07410676 ↗ “Fludarabine 160 mg/m\^2” NCT01238328 ↗ “Fludarabine: 30mg/m2/d” NCT05583175 ↗ “Fludarabine (Fludara®)” NCT07486089 ↗ “* Fludarabine (Flu)” NCT02988466 ↗ “Drugs:Fludarabine” NCT05667506 ↗ “Drug: Fludarabine” NCT06852573 ↗ “Fludarabine (FLU)” NCT01565616 ↗ “Drug: Fludarabine” NCT04232826 ↗ “Drug: Fludarabine” NCT04440436 ↗ “Drug: Fludarabine” NCT04160195 ↗ “Drug: Fludarabine” NCT05326243 ↗ “Drug: Fludarabine” NCT04586478 ↗ “Drug: Fludarabine” NCT04684147 ↗ “Drug: Fludarabine” NCT05947487 ↗ “* Fludarabine” NCT02179359 ↗ “* Fludarabine” NCT02171104 ↗ “Fludarabine” NCT01145976 ↗ “Fludarabine” NCT06325748 ↗ “Fludarabine” NCT07570563 ↗ “Fludarabine” NCT06316076 ↗ “Fludarabine” NCT06193889 ↗ “Fludarabine” NCT02665065 ↗ “Fludarabine” NCT06342960 ↗ “Fludarabine” NCT01050764 ↗ “Fludarabine” NCT06588491 ↗ “Fludarabine” NCT05938725 ↗ “Fludarabine” NCT06626919 ↗ “Fludarabine” NCT03914885 ↗ “Fludarabine” NCT03648697 ↗ “Fludarabine” NCT06385808 ↗ “Fludarabine” NCT05515185 ↗ “Fludarabine” NCT06400303 ↗ |
| Known as | 2-F-ara-AMP | “2-F-ara-AMP” NCT01168219 ↗1“2-F-ara-AMP” NCT00801489 ↗ |
| Known as | 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)- | “9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-” NCT02220985 ↗ |
| Known as | Beneflur | “Beneflur” NCT02727803 ↗ |
| Known as | F-araA | “50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to...” NCT03295058 ↗ |
| Known as | FAMP | “This is a phase I study of 7-hydroxystaurosporine (UCN-01) and fludararbine monophosphate (FAMP) in relapsed lymphoma.” PMID 21745173 ↗ Jul 2011 |
| Known as | Flu | “After the promising results of our preliminary study, we conducted a phase II prospective multicenter clinical trial using a fludarabine (Flu), cyclophosphamide (Cy), and...” PMID 20685256 ↗ May 201031“All patients received cyclophosphamide (CY), single fraction total body irradiation (TBI), and antithymocyte globulin (ATG) with or without fludarabine (FLU), followed by...” PMID 25824692 ↗ Mar 2015 “We hypothesized that lymphodepletion, achieved with cyclophosphamide (Cy) and fludarabine (Flu), would promote in vivo expansion of the infused lymphocytes enhancing their...” PMID 17579184 ↗ Jun 2007 “For participants identified as having stable or progressive disease (National Cancer Institute Criteria), Fludarabine (Flu) therapy will be added to VPA on a 28 day cycle.” NCT00524667 ↗ “The preparative regimen included high-dose (131)I-MIBG on day -20, followed by fludarabine (Flu), thiotepa, and melphalan (Mel) from day -8 to -1.” PMID 19660720 ↗ Jul 2009 “Patients in both groups received i.v. fludarabine (Flu) 30 mg/m(2)/day and i.v. busulfan (Bu) 0.8 mg/kg/day on days -5 to -2 as conditioning” PMID 19539216 ↗ Jul 2009 “Participants with Severe Aplastic Anemia will receive Fludarabine at 125 mg/m squared plus Cyclophosphamide at 60 mg/kg (Flu/Cy).” NCT01187017 ↗ “fludarabine (Flu) and cyclophosphamide (Cy), at different dosages, as the standard lymphodepletion regimen.” NCT07593482 ↗ “Fludarabine (Flu) is one part of the conditioning regimen. 150 mg/m2 (30 mg/m2 per day on days -6 to -2)” NCT06680661 ↗ “cyclophosphamide (Cy, 1000 mg/m2/day, day -6 to -5), and fludarabine (Flu, 25 mg/m2/day, day -6 to -2)” NCT04221971 ↗ “Fludarabine (FLU) is administered as a lymphodepletion regimen prior to NK042 infusion.” NCT06773091 ↗ “combination with Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen” NCT00800150 ↗ “Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)” NCT06152172 ↗ “after lymphodepletion with fludarabine (flu) and cyclophosphamide (cyc).” PMID 31110096 ↗ May 2019 “Fludarabine (Flu) was administered at 30mg/m2/day on days -5 to -2.” NCT07052422 ↗ “Fludarabine(Flu) was administered at 30mg/m2/day on days -6 to -3.” NCT03530085 ↗ “First, infusion over 60 minutes of Fludarabine (Flu) at 10 mg/m2” NCT04989335 ↗ “Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2” NCT01597778 ↗ “cyclophosphamide (Cy),low dose fludarabine (Flu)” NCT00597519 ↗ “Fludarabine (Flu): 30 mg/m²/day, days -7 to -3.” NCT07396480 ↗ “Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2)” NCT05884333 ↗ “the nucleoside analog fludarabine (Flu)” PMID 35154579 ↗ Feb 2022 “Chemotherapy: fludarabine (FLU)” NCT06451159 ↗ “Drug: Fludarabine (FLU)” NCT07410676 ↗ “* Fludarabine (Flu)” NCT02988466 ↗ “Fludarabine (FLU)” NCT04713956 ↗ “Fludarabine (FLU)” NCT07120607 ↗ “Fludarabine (FLU)” NCT05449899 ↗ “Fludarabine (FLU)” NCT07078721 ↗ “Fludarabine (FLU)” NCT03674411 ↗ “Fludarabine (FLU)” NCT05453552 ↗ “Fludarabine (FLU)” NCT07131085 ↗ |
| Known as | Flu-ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01145976 ↗ |
| Known as | Flud | “Fludarabine (Flud)” NCT07025824 ↗ |
| Known as | Fludara | “Subcutaneous MabCampath® (Alemtuzumab) and Oral Fludara® (Fludarabinephosphate) for the Treatment of Refractory or Relapsed Chronic Lymphocytic Leukemia” NCT00565981 ↗20“Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days” NCT00206726 ↗ “Fludarabine (Fludara®, Schering AG, Berlin, Germany) 30 ㎎/㎡ i.v. over 30 minutes in D5W 100 ㎖ on days -6 to -2” NCT00774280 ↗ “Drug: Fludarabine 30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3) Other Name: FLUDARA” NCT05211557 ↗ “busulfan (Bu), cyclophosphamide (Cy) and fludarabine (FLUDARA)” NCT00208923 ↗ “Other Names: Fludarabine Phosphate Fludara” NCT02809092 ↗ “Fludarabine (Fludara, Berlex Laboratories)” NCT01861106 ↗ “Fludarabine(Fludara, Berlex Laboratories)” NCT01176006 ↗ “Fludarabine, Fludara®, Bayer Shering” NCT00937300 ↗ “Fludarabine Phosphate (Fludara)” NCT00688883 ↗ “Fludarabine Phosphate (Fludara)” NCT00311129 ↗ “Fludarabine Phosphate (Fludara)” NCT00220311 ↗ “Fludarabine Phosphate (Fludara)” NCT00185445 ↗ “Fludarabine (Fludara)” NCT06802315 ↗ “Fludarabine (Fludara)” NCT06809712 ↗ “Fludarabine (Fludara)” NCT06809699 ↗ |
| Known as | Fludarabine (FLU) | “Fludarabine (FLU)” NCT01565616 ↗ |
| Known as | Fludarabine (Fludara) | “Fludarabine (Fludara®)” NCT07486089 ↗1“Fludarabine (Fludara)” NCT01877837 ↗ |
| Known as | Fludarabine (Fludara, Berlex Laboratories, Richmond, CA) | “Fludarabine (Fludara®, Berlex Laboratories, Richmond, CA)” NCT00815568 ↗ |
| Known as | fludarabine monophosphate | “Ad/PNP will be injected three times into the tumor over 2 days followed by three daily intravenous infusions of F-araAMP (fludarabine monophosphate).” NCT01310179 ↗11“Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.” NCT02809092 ↗ |
| Known as | fludarabine phosphate | “Patients receive fludarabine phosphate IV over 30 minutes and alemtuzumab IV over 30 minutes on days -7 through -3 and melphalan IV over 30 minutes on day -2.” NCT01256398 ↗313“Reduced-intensity preparative regimen: Patients receive fludarabine phosphate IV on days -6 to -2 and melphalan IV on day -1.” NCT00800150 ↗ “Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2.” NCT07066995 ↗ “Patients also receive fludarabine phosphate IV over 30 minutes on days 1-5 of weeks 1, 5, 9, 13, 17, and 21.” NCT00513747 ↗ “a drug called fludarabine phosphate, which is approved by the FDA for certain types of blood-cell cancers” NCT01310179 ↗ “Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3” NCT03672851 ↗ “patients receive fludarabine phosphate IV over 30 minutes” NCT00389506 ↗ “Other Names: Fludarabine Phosphate Fludara” NCT02809092 ↗ “Drug: fludarabine phosphate” NCT00002779 ↗ “Drug: fludarabine phosphate” NCT00281879 ↗ “Drug: fludarabine phosphate” NCT00043979 ↗ “Drug: fludarabine phosphate” NCT00004862 ↗ “Drug: Fludarabine Phosphate” NCT04250051 ↗ “Drug: fludarabine phosphate” NCT00255684 ↗ “Drug: fludarabine phosphate” NCT00258427 ↗ “Drug: fludarabine phosphate” NCT00027573 ↗ “Drug: Fludarabine Phosphate” NCT05761171 ↗ “Drug: fludarabine phosphate” NCT00003204 ↗ “Drug: fludarabine phosphate” NCT00121186 ↗ “Drug: Fludarabine Phosphate” NCT05418088 ↗ |
| Known as | Fludarabine phosphate (2-F-ara-AMP) | “Fludarabine phosphate (2-F-ara-AMP)” NCT01707004 ↗ |
| Known as | fludarabine phosphate (Fludara) | “fludarabine phosphate (Fludara)” NCT02784561 ↗ |
| Known as | Fludarabine Phosphate for Injection | “Fludarabine Phosphate for Injection” NCT06838832 ↗1“Fludarabine Phosphate for Injection” NCT06481735 ↗ |
| Known as | Fludarabine, Fludara, Bayer Shering | “Fludarabine, Fludara®, Bayer Shering” NCT00937300 ↗1“Fludarabine, Fludara®, Bayer Shering” NCT00937625 ↗ |
| Known as | fludarabine: Fludara(R) | “fludarabine: Fludara(R)” NCT00640796 ↗ |
| Known as | Fludarabinephosphat | “Drug: Fludarabinephosphat 5 doses (25 mg/m2, max. 50 mg) prior to infusion” NCT06204991 ↗ |
| Known as | fludararbine monophosphate | “This is a phase I study of 7-hydroxystaurosporine (UCN-01) and fludararbine monophosphate (FAMP) in relapsed lymphoma.” PMID 21745173 ↗ Jul 2011 |
| Known as | fludararbine phosphate | “Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.” PMID 21745173 ↗ Jul 2011 |
| Known as | Fludara | “Conditioning therapy will start on day -6 in patients who are randomized to receive Cy+fludarabine (Fludara®, Berlex Laboratories, Richmond, CA)+ATG.” NCT00774527 ↗ |
| Known as | Interventions:◦Drug: Fludarabine | “Interventions:◦Drug: Fludarabine” NCT01983761 ↗ |
| Known as | SENTI-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06325748 ↗ |
| Known as | SH T 586 | “Fludarabine Phosphate Tablet (SH T 586)” NCT00311129 ↗1“SH T 586” NCT03670966 ↗ |
| Action | Inhibit | “nucleoside analogs inhibits DNA repair” NCT00001676 ↗ |
| Modality | Small molecule | “nucleoside analogs chlorodeoxyadenosine and fludarabine” NCT00001676 ↗ |
| Route | Intravenous | “intravenous fludarabine” NCT00001422 ↗ |